ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Vonorasan fumarate injection1

Its studies are mostly in Peptic Ulcer Hemorrhage, led by Lunan Pharmaceutical Group.

Furthest: phase 2, since Jan 14, 20251 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lunan Pharmaceutical Group11 open or runningphase 2since Jan 14, 2025Jan 14, 2025Feb 2027phase 2 · NCT06783257

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2025First study: phase 2 study in Peptic Ulcer HemorrhageFirst studyNCT06783257 · 150 planned

Ahead

  1. Feb 2027Primary completion: phase 2 study in Peptic Ulcer HemorrhageNCT06783257

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06783257Peptic Ulcer Hemorrhage2Not yet recruitingFeb 2027150

How it is read

Names in the registry

  • “Vonorasan fumarate injection1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.